www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24220

Title: Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1
Authors: Rech, J.
Reinhardt, M.
Kavanaugh, A.
Geusens, Piet
Mpofu, S.
Issue Date: 2017
Publisher: WILEY
Citation: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 15(S1), p. 141-141 (Art N° P138)
Notes: [Rech, J.] Univ Erlangen Nurnberg, Dept Rheumatol & Immunol, Erlangen, Germany. [Reinhardt, M.] Novartis Pharma GmbH, Nurnberg, Germany. [Kavanaugh, A.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Geusens, P.] Maastricht Univ, Med Ctr, Maastricht, Netherlands. [Geusens, P.] Univ Hasselt, Hasselt, Belgium. [Mpofu, S.] Novartis Pharma AG, Basel, Switzerland.
URI: http://hdl.handle.net/1942/24220
ISI #: 000400154800356
ISSN: 1610-0379
Category: M
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
N/A150.17 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.